FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210472010> ?p ?o ?g. }

• W4210472010 endingPage "377" @default.
• W4210472010 startingPage "377" @default.
• W4210472010 abstract "Approximately 25% of colorectal cancer (CRC) patients will develop metastatic (m)CRC despite treatment interventions. In this setting, tumor cells are attracted to the epidermal growth factor receptor (EGFR) oncogene. Kirsten rat sarcoma (RAS) 2 viral oncogene homolog (KRAS) mutations were reported to drive CRC by promoting cancer progression in activating Wnt/β-catenin and RAS/extracellular signal-regulated kinase (ERK) pathways. In addition, KRAS is associated with almost 40% of patients who acquire resistance to EGFR inhibitors in mCRC. Multiple studies have demonstrated that cancer stem cells (CSCs) promote tumorigenesis, tumor growth, and resistance to therapy. One of the most common CSC prognostic markers widely reported in CRC is a cluster of differentiation 44 (CD44), which regulates matrix metalloproteinases 7/9 (MMP7/9) to promote tumor progression and metastasis; however, the molecular role of CD44 in CRC is still unclear. In invasive CRC, overexpression of MMP7 was reported in tumor cells compared to normal cells and plays a crucial function in CRC cetuximab and oxaliplatin resistance and distant metastasis. Here, we utilized a bioinformatics analysis and identified overexpression of KRAS/MMP7/CD44 oncogenic signatures in CRC tumor tissues compared to normal tissues. In addition, a high incidence of mutations in KRAS and CD44 were associated with some of the top tumorigenic oncogene's overexpression, which ultimately promoted a poor response to chemotherapy and resistance to some FDA-approved drugs. Based on these findings, we explored a computational approach to drug repurposing of the drug, sulfasalazine, and our in silico molecular docking revealed unique interactions of sulfasalazine with the KRAS/MMP7/CD44 oncogenes, resulting in high binding affinities compared to those of standard inhibitors. Our in vitro analysis demonstrated that sulfasalazine combined with cisplatin reduced cell viability, colony, and sphere formation in CRC cell lines. In addition, sulfasalazine alone and combined with cisplatin suppressed the expression of KRAS/MMP7/CD44 in DLD-1 and HCT116 cell lines. Thus, sulfasalazine is worthy of further investigation as an adjuvant agent for improving chemotherapeutic responses in CRC patients." @default.
• W4210472010 created "2022-02-08" @default.
• W4210472010 creator A5006029624 @default.
• W4210472010 creator A5027031813 @default.
• W4210472010 creator A5072552169 @default.
• W4210472010 creator A5086212262 @default.
• W4210472010 creator A5089617153 @default.
• W4210472010 creator A5091150494 @default.
• W4210472010 date "2022-02-04" @default.
• W4210472010 modified "2023-10-18" @default.
• W4210472010 title "Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling" @default.
• W4210472010 cites W1658415069 @default.
• W4210472010 cites W1928327536 @default.
• W4210472010 cites W1944656365 @default.
• W4210472010 cites W1988652768 @default.
• W4210472010 cites W2003500892 @default.
• W4210472010 cites W2008330966 @default.
• W4210472010 cites W2015099229 @default.
• W4210472010 cites W2015925550 @default.
• W4210472010 cites W2020839323 @default.
• W4210472010 cites W2033364737 @default.
• W4210472010 cites W2034580741 @default.
• W4210472010 cites W2040178251 @default.
• W4210472010 cites W2041813750 @default.
• W4210472010 cites W2062109911 @default.
• W4210472010 cites W2070686081 @default.
• W4210472010 cites W2082848986 @default.
• W4210472010 cites W2097121246 @default.
• W4210472010 cites W2098223440 @default.
• W4210472010 cites W2103502575 @default.
• W4210472010 cites W2106789440 @default.
• W4210472010 cites W2107053205 @default.
• W4210472010 cites W2107644337 @default.
• W4210472010 cites W2107979823 @default.
• W4210472010 cites W2112327424 @default.
• W4210472010 cites W2122885616 @default.
• W4210472010 cites W2132834292 @default.
• W4210472010 cites W2132946679 @default.
• W4210472010 cites W2134519717 @default.
• W4210472010 cites W2134967712 @default.
• W4210472010 cites W2136357864 @default.
• W4210472010 cites W2142564546 @default.
• W4210472010 cites W2150840254 @default.
• W4210472010 cites W2150919598 @default.
• W4210472010 cites W2153007740 @default.
• W4210472010 cites W2155311724 @default.
• W4210472010 cites W2156149964 @default.
• W4210472010 cites W2157824687 @default.
• W4210472010 cites W2165244997 @default.
• W4210472010 cites W2210634983 @default.
• W4210472010 cites W2319075026 @default.
• W4210472010 cites W2404698635 @default.
• W4210472010 cites W2548615291 @default.
• W4210472010 cites W2596043126 @default.
• W4210472010 cites W2728306231 @default.
• W4210472010 cites W2777158133 @default.
• W4210472010 cites W2795718561 @default.
• W4210472010 cites W2802981934 @default.
• W4210472010 cites W2804658429 @default.
• W4210472010 cites W2885239461 @default.
• W4210472010 cites W2891141728 @default.
• W4210472010 cites W2892203931 @default.
• W4210472010 cites W2900524781 @default.
• W4210472010 cites W2909222252 @default.
• W4210472010 cites W2921090392 @default.
• W4210472010 cites W2922400274 @default.
• W4210472010 cites W2943146366 @default.
• W4210472010 cites W2947901217 @default.
• W4210472010 cites W2955341169 @default.
• W4210472010 cites W2965145700 @default.
• W4210472010 cites W2966597246 @default.
• W4210472010 cites W2972509427 @default.
• W4210472010 cites W2979717539 @default.
• W4210472010 cites W2981712643 @default.
• W4210472010 cites W3035641314 @default.
• W4210472010 cites W3045398807 @default.
• W4210472010 cites W3045763729 @default.
• W4210472010 cites W3082325112 @default.
• W4210472010 cites W3108159980 @default.
• W4210472010 cites W3108977744 @default.
• W4210472010 cites W3135882325 @default.
• W4210472010 doi "https://doi.org/10.3390/biomedicines10020377" @default.
• W4210472010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35203586" @default.
• W4210472010 hasPublicationYear "2022" @default.
• W4210472010 type Work @default.
• W4210472010 citedByCount "3" @default.
• W4210472010 countsByYear W42104720102022 @default.
• W4210472010 countsByYear W42104720102023 @default.
• W4210472010 crossrefType "journal-article" @default.
• W4210472010 hasAuthorship W4210472010A5006029624 @default.
• W4210472010 hasAuthorship W4210472010A5027031813 @default.
• W4210472010 hasAuthorship W4210472010A5072552169 @default.
• W4210472010 hasAuthorship W4210472010A5086212262 @default.
• W4210472010 hasAuthorship W4210472010A5089617153 @default.
• W4210472010 hasAuthorship W4210472010A5091150494 @default.
• W4210472010 hasBestOaLocation W42104720101 @default.
• W4210472010 hasConcept C121608353 @default.
• W4210472010 hasConcept C126322002 @default.

• next